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ABSTRACT: Sunitinib is the standard-of-care, first-line treatment for advanced renal cell carcinoma 
(RCC). Characteristics of treatment-resistant RCC have been described; however, complex tumor 
adaptation mechanisms obstruct the identification of significant operators in resistance. We 
hypothesized that resistance is a late manifestation of early, treatment-induced histomolecular 
alterations; therefore, studying early drug response may identify drivers of resistance. We describe an 
epithelioid RCC growth pattern in RCC xenografts, which emerges in sunitinib-sensitive tumors and is 
augmented during resistance. This growth modality is molecularly and morphologically related to the 
RCC spheroids that advance during in vitro treatment. Based on time-lapse microscopy, mRNA and 
microRNA screening, and tumor behavior-related characteristics, we propose that the spheroid and 
adherent RCC growth patterns differentially respond to sunitinib. Gene expression analysis indicated 
that sunitinib promoted spheroid formation, which provided a selective survival advantage under 
treatment. Functional studies confirm that E-cadherin is a key contributor to the survival of RCC cells 
under sunitinib treatment. In summary, we suggest that sunitinib-resistant RCC cells exist in treatment-
sensitive tumors and are histologically identifiable. 
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INTRODUCTION 
Renal cell carcinoma (RCC) is among the 10 most common cancers in North America, and 85% of RCC 
cases fall within the clear cell renal cell carcinoma (ccRCC) subtype. The multitargeted receptor 
tyrosine kinase (RTK) inhibitor sunitinibisthestandard, first-line treatment for the 30% of patients with 
RCC who develop distant metastases (1). Although 47% of patients with metastatic RCC (mRCC) initially 
respond to sunitinib (2), long-term response and complete remission are rare because of acquired 
resistance (3). Since the FDA approved sunitinib for the treatment of mRCC, much work has been done 
to uncover the molecular mechanisms that contribute to resistance (2, 4–9). The dynamics of the 
potential sunitinib-adaptation mechanisms, however, and therefore, the root of resistance, remain 
unexplored. With recent promising results of immunecheckpointtherapies, there is an emerging 
interest in the combination of different immune therapies as well as the combination of an 
immunetherapy with RTKs. Teasing outthemostpotentcombinationtreatmentwillbeaidedby 
preclinicalmodels, and characterization of RTK resistance will be crucial in investigating the interaction 
between immunetherapyandRTK-resistantcancercells. Previous studies aimed to capture the drivers 
of sunitinib resistance by comparing sunitinib-sensitive and sunitinib-resistant specimens. That 
approach, however, neglectsdriversthatmayalreadyoperateatthesensitive stage. We hypothesized 
that the sensitive and resistant stages were at different time points of the single continuum of 
molecular events induced by sunitinib. Therefore, studying molecular and related histologic changes 
that occur early during treatment may identify the relevant alterations that invoke resistance. 
Inthisstudy, we used in vitro and in vivo models (both allogeneic and syngeneic xenograft models) to 
examine the effect of sunitinib treatment on kidney cancer cells during both sensitive and resistant 
stages. Our results show that sunitinib treatment provides selective advantage for RCC cells that are 
able to form tight epithelioid spheroids in vitro or the corresponding morphology in vivo. Furthermore, 
we show that the resistant morphology isinducedbythetreatment. 
MATERIALS AND METHODS 
Cell culturing and in vitro treatment 
ACHN, 786-0, and Renca cells were obtained from American Type Culture Collection (Manassas, VA, 
USA) and were culturedperthedistributor’sdescription.Cells were treated with 1 mM sunitinib-malate 
(Selleckchem, Houston, TX, USA) dissolved in DMSO or with DMSO only (vehicle). When cells were 
passaged, floating cells were also collected from the 
mediumbycentrifugationandweretrypsinizedtogetherwith the adherent cells. RCC spheres were 
passaged as described below. Resistance index was measured and calculated as previously described 
(10, 11). 
Secondary and tertiary sphere formation 
RCC spheres were picked under a microscope and were trypsinized and further disrupted by pipetting 
through a 200-ml pipette tip or a 30-gauge needle. Sphere disruption was 
monitoredunderamicroscope. Cells (23104cells/well)were plated on 6-well plates (Sarstedt, 
N¨umbrecht, Germany) and coated with Matrigel (Thermo Fisher Scientific, Waltham, MA, USA). Cells 
were then stained with Hoescht-3422, and cell number/well was determined by ImageXpress Micro 
Acquisition System (Molecular Devices, Sunnyvale, CA, USA), using the IMX software 
(IMXSoftwareGroup,London, England). The minimum sphere size was 40 mm, and the maximum 
spheroid size was 250 mm. 
Mouse tumor models Syngeneic xenograft model 
BALB/c mice (6–8 wk old, female; Charles River Laboratories, 
Wilmington,MA,USA)wereinjectedwith53105cells,s.c.inthe femur area. Injection contained a 1:1 ratio 
of Matrigel (Thermo FisherScientific)andsingle-cellsuspension. 
Allogenic xenograft model 
NOD/SCIDg (NSG) mice (6–8 wk old, female; The Jackson Laboratory, Bar Harbor, ME, USA) were 
injected with 5 3 105 cells subcutaneously in the femur area. Injection contained a 1:1 ratio of Matrigel 
(Thermo Fisher Scientific) and single-cell suspension. 
In vivo sunitinib treatment 
Miceweretreatedwith40mg/kgsunitinib(Selleckchem)orwith citratebuffer(vehicle-
treatedgroup)bygavage,7d/wk.Sunitinib treatment startedonce xenografts reached the estimated 
volume of 100 mm3 (for Renca xenografts) or 50 mm3 (for ACHN xenografts). Tumor size was 
monitored daily by manual caliper, and tumorvolumewasestimatedwiththefollowingequation: 
Volume¼ðwidthÞ2 3ðlengthÞ 2 
Spontaneous metastasis model 
FiftyACHNor103 RencacellswithanequalvolumeofMatrigel were subcutaneously injected into the neck 
area of 6–8-wk-old, female BALB/c or NSG mice. Tumor formation was monitored 
3d/wk.Micewereeuthanizedat27d(Renca-recipientmice)or 60d(ACHN-recipientmice)afterinoculation. 
Tail-vein injection metastasis assay 
Renca(53103)orACHNcellswereinjecteddirectlyintothetail vein of 6–8-wk-old female BALB/c or NSG 
mice. Metastatic disease was monitoredby observingchanges in bodycondition (hunched back, loss of 
body weight, and dehydration). Rencarecipient mice were euthanized 40 d after inoculation, and 
ACHN-recipientmicewereeuthanized80dafterinoculation. 
Histologic assessment 
Tumorsandorgans(liver,kidneys,lungs,spleen,stomach,guts, 
andanyareasuspiciousformetastasis)werecollectedandsnapfrozenforRNAanalysisorfixedin10%formali
n.Allspecimens were paraffin embedded, and 5–8-mm sections were prepared 
andstainedwithhematoxylinandeosin.Twopathologists(S.R. andG.M.Y.) 
independentlyassessedthestainedsections. 
Immunohistochemistry 
Specimens were fixed in PBS-buffered 10% formalin and embedded in paraffin. The following 
antibodies were used: Ki-67 [1:100, heat-induced epitope retrieval (HIER), cell conditioner 
1(CC1)for32min;BiocareMedical,Concord,CA,USA],b-catenin (1:400, clone 14, HIER, CC1 for 64 min; 
Cell Marque, Rocklin, CA, USA), E-cadherin (1:50, HIER, CC1 for 64 min; Inter Medico, Markham, ON, 
Canada), pancytokeratin (pan-CK; prediluted,cloneae1/ae3/pck26,protease1–4,CC1for16min; 
F.Hoffmann-LaRoche,Basel,Switzerland),low-MWCK(1:20, CAM5.2,protease1–
4min;BectonDickinson,FranklinLakes, NJ, USA). Antigen retrieval was performed on automated 
Ventana Discovery Ultra (F. Hoffmann-La Roche). 
Immunocytochemistry 
Spheroids were stained as described by Weiswald et al. (12). Anti–E-cadherin and anti–b-catenin 
antibodies were purchased from Santa Cruz Biotechnology (sc-7963; Dallas, TX, USA) and Cell Signaling 
Technology (4627; Danvers, MA, USA) and were used as directed by the manufacturers. DAPI staining 
was performedtovisualize the nuclei. 
RNA isolation and quantitative RT-PCR analysis 
Tumors were snap-frozen and stored at 280°C for RNA 
isolation.TotalRNAwasisolatedwiththemicroRNA(miRNA)kit (miRNeasy Isolation Kit; Qiagen, Hilden, 
Germany) following the manufacturer’s recommendations. Reverse transcription for 
mRNAanalysiswasperformedwiththeHighCapacityRNA-tocDNA Kit (Thermo Fisher Scientific), as 
recommended by the manufacturer.RNAqualityandquantityweredeterminedwith 
aBioanalyzerRNAChip(AgilentTechnologies,SantaClara,CA, 
USA)andaNanoDrop2000Spectrophotometer(ThermoFisher 
Scientific).QuantitativePCRreactionswereperformedonViia7 Real-Time PCR System (Thermo Fisher 
Scientific), using the SYBR Green Master Mix (Thermo Fisher Scientific). Cycle 
thresholdvalueswerenormalizedagainstthegeometricmeanof glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), peptidylprolyl isomerase A (PPIA), ribosomal protein lateral stalk 
subunitP0(RPLP0),andhypoxanthine phosphoribosyltransferase1(HPRT1).TheDDCt 
methodwasusedtoobtaintherelative quantificationvalues. 
Imaging 
LiveimagingwasperformedwithanAxioObserverLiveCellwith Fluorescence Lifetime Imaging instrument 
(Carl Zeiss, Oberkochen,Germany),andimageswereanalyzedwithZenBlack(Carl Zeiss). Confocal 
microscopy was performed with a Carl Zeiss LSM700. For spheroid counting, cultures were stained 
with Hoechst33342,andautomatedspheroidcountingwasperformed 
byImageXpressMicroAcquisitionSystem.Minimalspheroidsize wasadjustedto40 
mm,andmaximumsizewas250 mm. 
Proliferation and apoptosis assay 
AproliferationassaywasperformedbyWST-1(MilliporeSigma, Billerica, MA, USA). Absorbance was 
measured at 650 and 450 nm with a SpectraMax M5 spectrophotometer (Molecular Devices). Because 
of the broad fluorescence spectrum of sunitinib,cytotoxicitywasquantifiedwiththeLive/DeadFixableFar 
RedDeadCellStainKit(ThermoFisherScientific).FlowcytometryanalysiswasperformedonaBDLSRFortessa
X-20system. 
Statistics 
Data were analyzed with the Prism 7 package (GraphPad Software, La Jolla, CA, USA). We used 1-way 
ANOVA to visualize the tumor-growth curves and to analyze mRNA expression values. 
Microarray and nanostring expression analysis 
Microarray gene expression was performed at Centre for 
AppliedGenomicsofTheHospitalforSickChildren(Toronto,ON, Canada). A Nanostring Encounter Human 
miRNA Expression AssayKitwasusedtoprofiletheexpressionof800miRNAs.Data were processed with 
the R Bioconductor 3.2.3 software (R Foundation for Statistical Computing,Vienna,Austria). Affymetrix 
Mouse Gene 2.0 ST transcriptome array (Thermo Fisher Scientific) data were processed using R 
functions contained withinaffypackage1.48.0,andthebackgroundofthearrayswas 
correctedbyrobustmultiarrayaveraging.TheHT-12Expression BeadChip Kit (Illumina, San Diego, CA, 
USA) array data were processed using R functions contained within the Beadarray 2.20.1 package, 
whereas the NanoString data were processed 
withfunctionswithinNanoStringNormpackage(RFoundation), and probes with ,30 read count for all the 
samples were excluded. In all 3 studies—human arrays, mouse arrays, and Nanostring—between-
sample/arrayquantilenormalization was performed, followed by the gene expression changes 
between groups using a t test (for 2 groups) and subjected to correction for multiple testing with the 
Benjamini-Hochberg false-discovery rate, in the limma package 3.26.9. The data sets supporting the 
conclusions in this article are available in the Gene Expression Omnibus database (National Center for 
Biotechnology Information, Bethesda, MD, USA). Lentiviral transduction 
Third-generation, self-inactivating lentiviral vectors (LVs) were produced by cotransfection of human 
embryonic kidney 293T cells with polyethylenimine and packaging plasmids pMDL-g/pRRE, pMD2-
VSVg, and pRSV-Rev (Addgene, Cambridge,MA,USA)aswellastheLVtransfervectorscarryingthe short 
hairpin RNA (shRNA) sequences against E-cadherin (TRCN0000039665, TRCN0000039664, and 
TRCN0000039667; Dharmacon,Lafayette,CO,USA).Oligonucleotidesequenceand the position of the 
shRNAs were as follows TRCN0000039664 forward, 
59‑CCGGCCAGTGAACAACGATGGCATTCTCGAGAATGCCATCGTTGTTCACTGGTTTTTG‑39,reverseoligo 
sequence, 59‑AATTCAAAAACCAGTGAACAACGATGGCATTCTCGAGAATGCCATCGTTGTTCACTGG‑39, 
match position, 1562; TRCN0000039665 forward, 
59‑CCGGCCAAGCAGAATTGCTCACATTCTCGAGAATGTGAGCAATTCTGCTTGGTTTTTG‑39, reverse, 
59‑AATTCAAAAACCAAGCAGAATTGCTCACATTCTCGAGAATGTGAGCAATTCTGCTTGG‑39, match 
position, 682; and TRCN0000039667 forward, 
59‑CCGGCCAACCCAAGAATCTATCATTCTCGAGAATGATAGATTCTTGGGTTGGTTTTTG‑39, reverse, 5 
9‑AATTCAAAAACCAACCCAAGAATCTATCATTCTCGAGAATGATAGATTCTTGGGTTGG‑39, match position, 
2210. Subsequently, LVs were concentrated by ultracentrifugation of the human embryonic kidney 
293T cell medium at 20,000 rpm for 2 h at 4°C and stored at 280°C. Cells were transduced with 
lentivector with a multiplicity of infection of 10. 
RESULTS 
Sunitinib-treated tumor xenografts exhibit aggressive tumor behavior that starts early during response 
phase and is marked by unique histomorphologic changes 
Weusedxenograftmodelstoassesstheeffectofsunitinibon cancer cells in vivo. BALB/c mice were 
xenografted with Renca RCC cells and were used as the immunocompetent model (n = 20). The Renca 
cell line was established from a tumor that arose spontaneously as a renal cortical adenocarcinoma in 
BALB/cCr mice. This cell line gives a high number of spontaneous metastases to the lung and liver, 
accurately mimicking human adult renal cell carcinoma, thus making Renca the most used 
immunocompetent murine model for RCC. To assess the behavior of human RCC, 786-0 and ACHN cell 
lines were used in this study, with the 786-0 cell line derived from a primary RCC site, and showing 
canonical clear cell histology, depicting the mostcommonRCCsubtype.The786-0cellslackfunctional von 
Hippel-Lindau tumor suppressor protein expression, 
whichisawidelyaccepteddriverofccRCC.TheACHNcell line was isolated from a malignant pleural RCC 
effusion. NSG mice were used as a host for human-derived tumor xenografts.Inadditiontothe scid 
mutation,whichrenders the strain deficient in T and B cells, NSG mice are also deficient in functional 
NK cells, minimizing rejection. NSG mice were xenografted with 786-0 RCC cells and were used as an 
immunocompromised model (n = 12). Mice were randomized to vehicle-treated and sunitinib-treated 
groups.Treatmentresponsewasassessedbasedonthetumor growth curve. Most xenografts exhibited 
initial drugsensitivity(flattumorgrowthcurve),followedbyresistance (steep increase in growth tumor 
curve). The tumors that were harvested at the time of rapid growth after an initial 
responsewereconsideredtreatmentdefiantandwereused as the sunitinib-resistant cohort (Fig. 1). 
Some xenografts, however, showed an extended drug-sensitive period and wereusedasthesunitinib-
sensitivecohort(Fig.1A). Sunitinib-sensitive xenografts of both Renca and 7860 cell lines showed early 
signs of aggressive behavior, which manifested as irregular invasive borders, local 
invasion,andextensivemetastaticdeposits.Multinucleated giant cells, which are described as indicators 
of genomic instability (13), were also frequent in the sensitive 
xenografts.Thesefeaturesbecameevenmoreprominentinthe sunitinib-resistant xenografts 
(Supplemental Fig. S1 and SupplementalTableS1). Strikingly, sunitinib-treated tumors showed viable, 
compact tumor islands (tongues of tumors within necrotic spaces), which contrasted with the 
confluent necrosis observed in vehicle-treated tumors. These tumor tongues were epithelioid and 
expressed mesenchymal and epithelial markers (vimentin, CKs). PAX8 
stainingconfirmedtheirrenalorigin(Fig.1B).Budding of those epithelioid nests was observed at the 
tumor front. Such a phenomenon is associated with invasive potential and poor prognosis in other 
cancers and indicates the aggressive potential of the surviving RCC tumor tongues. 
In vitro sunitinib treatment induced formation of RCC spheroids with increased colonization potential 
and expression of stem cell markers 
Tobetterunderstandsunitinib’searlyeffectoncancercells, ACHN and Renca cells were treated with 
sunitinib in vitro.Sunitinibsensitivityorresistancewasassessedbythe 
resistanceindex(10,11).Treatedculturesshowedincreased expression of stem cell–related markers, 
such as OCT4, NANOG, Kruppel-like factor 4 (KLF4), and stem cell 
markersofkidneyandothercancers,suchasneuronalcell adhesion molecule (NRCAM), CD105, leucine-
rich repeat containing G protein-coupled receptor 5 (LGR5), ABCC9, 
andGLIS2(SupplementalFig.S2)(14).Thesechangeswere detected early, within 1 wk of treatment and 
before the onsetofresistance.QuantitativePCRanalysisdidnotsuggestepithelial–
mesenchymaltransition(EMT)changes. We previously described the formation of RCC spheroid 
structures with low efficiency under standard culturing conditions (15). Compared with the DMSO 
control, sunitinib increased the spheroid formation rate by 8-fold, starting as early as d 2 after 
treatment (Fig. 2A–C). To investigate whether sunitinib also affected the ability of spheroids to 
differentiate into adherent cells, we dissociated and propagated RCC spheroids in the presence of 
DMSO or sunitinib and quantified the number of spheroids that were formed and the ratio of cells that 
engaged in spheroid formation. Sunitinib did not significantly increase the number of secondary and 
tertiary spheroids. The rate of cells that participated in spheroid formation, however, significantly 
increased under sunitinib treatment,comparedwiththeDMSO-treatedcontrol.This indicates that 
sunitinib created an imbalance between 2-dimensional (2D) and 3-dimensional (3D) growth patterns 
(Fig. 2D, E), either by inhibition of adherent growth orbyselectingforthespheroidarchitecture. Sunitinib 
has previously been reported to enhance RCCmetastasisinaneoadjuvantsetting(16,17).Inour 
xenograftmodel,ACHNandRencacellsretainedtheir tumorigenic and metastatic ability, regardless of 
sunitinib treatment and growth modality. We thought to separately examine extravasation potential 
of RCC cells because it is a crucial step in metastasis. During tail-vein assay, cancer cells are directly 
injected into the host’s circulatory system. This assay tests the potential of cancer cells to exit the 
vasculature and generate metastatic deposits. To explore the relation among the extravasation 
potential of RCC cells, sunitinib treatment, and spheroid formation, the following 4 subpopulations of 
ACHN and Renca cells were injected into mice tail-vein: 1) vehicle-treated, adherent; 2) vehicle-
treated, RCC spheroids; 3) sunitinib-treated, adherent; and 4) sunitinib-treated, RCC spheroids. Mice 
injected with the ACHN spheroid-derived suspension formed 10 times 
moremetastaticdepositsinthelungsandlivercompared 
withadherentcells.Additionally,spheroidsmetastasized to the kidney, which was rarein the case of the 
adherent RCC cells. In line with the more aggressive nature of the Renca cells, all mice developed 
metastases. However, spheroid-injectedmicehadsignificantlymoredepositsin 
thelungsandhadshortersurvival(SupplementalFig.S3). 
Takentogether,sunitinibledtotheaccumulationofRCC spheroids with increased stem cell–related 
marker expression, and enhanced extravasation potential. Of note, the overall metastatic ability of 
RCC spheroids was similar to that of the adherent patterns, rather than the extravasation, and/or 
subsequent survival of metastases wasincreased.Increasedextravasationpotentialofother 
cancerspheroidshasbeenreported (18). 
Sunitinib preferentially affects adherent RCC cells compared with spheroid-forming cells 
We have shown that sunitinib treatment favored RCC 
spheroidgrowthinvitro.Toverifythedifferentialresponse of RCC spheroids and adherent cells to 
sunitinib, we monitored RCC growth dynamics under treatment by real-time microscopy for 55 h. We 
tested 4 conditions: 1) cells untreated for 1 wk that remained untreated during the time-lapse imaging; 
2) cells pretreated with sunitinib for 1 wk with continued treatment during imaging; 
3)cellsuntreatedfor1wkandthenswitchedtosunitinibtreatment during imaging; and 4) cells pretreated 
with sunitinib for 1 week and switched to no treatment 
duringimaging(Fig.3A).Untreatedcellspredominantly grew as an adherent, 2D monolayer, whereas 
sunitinibtreated cells showed significantly more spheroid formations (Fig. 3B, C). Untreated cells 
reached confluence at 25–32 h of imaging, indicating high proliferation 
andmigrationability(condition1).Conversely,sunitinib treatment enhanced spheroid formation, 
whereas adherent colonies were unable to advance (condition 2). Likewise, when cells were switched 
to sunitinib-treatment (condition 3), RCC spheroids grew in diameter, whereas adherent cell growth 
was inhibited. In condition 4, sunitinib withdrawal promoted 2D adherent growth, whereas the 
spheroids lost their compact morphology andwerereplacedbyamonolayergrowthpattern(Fig.3). 
QuantificationbyImageXpressconfirmedthatsunitinibhad a contrasting effect on the different RCC 
growth patterns, favoring3Dspheroidsandlimiting2Dmonolayergrowth. 
Overlapping molecular signatures mark spheroid formation and sunitinib treatment 
To gain information about the molecular pathways associated with spheroid formation and with 
sunitinib treatment and to assess whether those were related, we compared global mRNA and miRNA 
expression between the aforementioned 4 subpopulations in ACHN and Renca cell lines. Comparison 
of DMSOtreated ACHN spheroids and DMSO-treated adherent cells with stringent criteria (fold change, 
.3; falsediscovery rate, ,4%) indicated the up-regulation of cell adhesion and its auxiliary gene ontology 
(GO) categories, such as membrane trafficking, vesicular transport, and cell polarity in the spheroids. 
These results suggest that cell aggregation through the relocalization of adhesion factors is a primary 
contributor to spheroid formation (Fig. 4A). Adherent ACHN cells were treated with vehicle or 
sunitinibfor2dtoinvestigateearlyresponse.Wenoteda significant overlap between pathways that were 
induced in the adherent ACHN cells upon treatment and pathways that were induced during spheroid 
formation. Cell-adhesion–relatedGOcategories,suchascytoskeletal dynamics, vesicular transport, and 
disruption of cell polarity were overrepresented in the treated adherent cells. Additionally, sunitinib 
induced the small GTPasemediated signaling along with several developmental 
processes,suchastubedevelopment,negativeregulation of development, and anatomic structure 
morphogenesis. Down-regulated categories included kinetochore organization, regulation of 
microtubule cytoskeleton organization,andregulationofmitoticnucleardivision.Increased 
presenceofthemultinucleatedgiantcellsinthesunitinibtreated xenografts morphologically supported 
these results.Theoverlapbetweenmoleculareventsthatoccurin spheroids and during early sunitinib 
treatment of adherent cells indicate that sunitinib may generate a cell status that endorses spheroid 
formation and opposes the 2D adherentstate.Thissuggestionissupportedbytheinvitro 
observationthatsunitinibincreasedthespheroidnumber. Among the signaling pathways, PI3K 
signaling/AKT activation, cell–cell interaction, and G protein-coupled 
receptors(GPCRs)activationwerethemostsignificantlyupregulated under treatment. AKT is activated by 
RTKs, GPCRs,andcell–celladhesionmolecules,suchascadherins (19–21). Because sunitinib reportedly 
inhibits most RTKs(22),itisplausiblethatPI3K/AKT-basedsurvivalrelies on alternative inputs under 
treatment. For example, GPCR and cadherin-mediated activation could compensate for the 
lostinput,thuspropellingsurvival(Fig.4B).Additionally, sunitinib-treated spheroids overexpressed 
cytoskeletal/ microtubularproteinsandsmallGTPasesandalsoshowed overrepresentation of 
developmental categories, such as anatomic structure and morphogenesis. Transcriptome analysis of 
the 4 Renca subpopulations showed similar results. Overall, transcriptome analyses revealed the 
operation of overlapping molecular mechanisms during early response to sunitinib and spheroid 
formation. Our results suggest that sunitinib treatment supports spheroid formation by promoting 
cell–cell contact andvesicle-mediatedtransport. 
miRNA expression analysis reveals different treatment responses in adherent vs. spheroid-forming RCC 
cells 
Vehicle-treated adherent, vehicle-treated spheroid, sunitinib-treatedadherent,andsunitinib-
treatedspheroid AHCNcellswereevaluatedformiRNAexpression.Ofthe 825 screened miRNAs, 246 
miRNAs were significantly anddifferentiallyexpressedin$1comparison.Sunitinibtreatment had a 
greater effect on adherent cells than on spheroid-forming cells. miR-1268b, miR-302b, miR-579, 
andmiR-1185-2-3pweresignificantlygreaterinadherent cells, whereas miR-7-5p was up-regulated in 
the DMSOtreated adherent cells only. We have not identified 
miRNAsthatwerespecificforthespheroidsbutwerenot 
relatedtosunitinibtreatment,supportingourhypothesis that sunitinib treatment promoted spheroid 
formation andcounterbalanced adherentgrowth. OurdataindicatedthatmiRNAshadasignificanteffect 
on ubiquitin-mediated proteolysis under sunitinib treatment,andmiR-
579appearedtobeakeyregulatorofthat process.TheBMPreceptor-andactivinreceptor-mediated 
branchesofTGF-b signalingappearedtobedifferentially regulated in adherent RCC cells vs. spheroids. 
DifferentiationdrivenbytheNODAL(nodalgrowthdifferentiation factor)/ACVR2 (activin A receptor type 
2A)/SMAD2/ SMAD4 axis appeared to be under miRNA inhibition in theRCCspheresbutnotinadherent 
ACHNcells. Overall, mRNA and miRNA expression converged on the regulation of intracellular vesicular 
trafficking (SupplementalFig.S4). Tumor islands that appear during early sunitinib treatment in vivo 
share characteristics with RCC spheroids that emerge under sunitinib treatment in vitro 
To establish the link between the in vitro spheroids and the surviving tumor islands in vivo, we 
performed immunohistochemistry (IHC) for E-cadherin and bcatenin expression and localization, 
based on our in vitromRNAexpressiondatashowingcell–celladhesionas the most significant difference 
between adherent and spheroid-forming cells. Both spheroids (in vitro) and epithelioid tongues (in 
vivo) showed membranous positivity forE-cadherinandstainedpositiveforb-catenin,whereas DMSO-
treated adherent cells (in vitro) and other xenograft tumor areas (in vivo) exhibited low levels of 
cytoplasmic (but not membranous) E-cadherin staining and werenegativefor b-catenin(Fig. 5A,B). 
Further, we injected either adherent cells or spheroids into mice to evaluate the histology of their 
xenografts. ACHN spheroid xenografts exhibited a spectrum of morphologic patterns, including 
epithelioid nests, cytoplasmic clearing (typical ccRCC morphology), and spindled pattern (23). 
Additionally, compact, epithelioid tumor tongues were frequently observed. Tumors were invasive to 
fat and had multiple small, distant metastases and vascular co-option in the lungs (Fig. 5). Overall, the 
growth pattern was similar to that of the sunitinibsensitive xenografts. In contrast, adherent RCC-
derived xenografts were mostly spindle shaped with no morphologic diversity and with minimal 
presence of tumor tongues (Fig. 5C–E and Supplemental Table S2). Weconcluded that the in vitro and 
in vivo growth patterns were related,andE-cadherinthatexpressedlivetumortongues in sunitinib-
treated xenografts reflected the in vitro RCC spheroidsthat emergedundersunitinibtreatment. 
E-cadherin-based cell–cell contact protects RCC spheres from sunitinib-mediated cell death with 
vehicle, and apoptosis and proliferation were quantifiedafter72h.Sunitinibhadasignificantcytotoxic 
effect on adherent cells, whereas it did not increase apoptosis in the RCC spheroids (Fig. 6A–C). 
Consistent with our real-time microscopy data, spheroid cultures showedincreased proliferation under 
sunitinib treatment, whereas the proliferation of adherent cells did not change significantly (Fig. 6D). 
Because 
Sunitinib exerted a contrasting effect on the different growth modalities of RCC. To evaluate whether 
disparate response was reflected by alterations in commonly tested tumor characteristics, adherent 
and spheroid ACHN cultures were treated with sunitinib or cadherin-mediated cell–cell adhesion was 
a top upregulated GO category in sunitinib-treated cells and spheroids, we thought to assess whether 
cadherinmediated cell–cell contact could promote survival of RCC spheres under treatment. Cells were 
switched to Ca2+-free condition to disrupt cadherin-mediated adhesions (24) and were treated with 
sunitinib for 72 h. Ca2+-free condition sensitized RCC spheroids to 
sunitinibtreatment,whichmanifestedasincreasedratio of apoptotic cells in addition to decreased 
proliferative capacity (Fig. 6B, D). To determine whether E-cadherin was specifically 
involvedinprotectingspheroidsundersunitinibtreatment, cultures were transduced by lentiviral 
particles carrying appropriate shRNAs. Adherent and spheroid cultures 
weresubsequentlytreatedwithsunitinibfor72h.Viability 
andproliferationofRCCspheroidsdecreasedsignificantly in response to E-cadherin inhibition. In 
contrast, sunitinib’s cytotoxicity did not change when spheroids were transduced with control 
enhanced green fluorescent protein lentiviral particles, whereas a nonsignificant increase in 
proliferation was observed (Fig. 6C, E). In vivo, the proliferative marker Ki-67 showed markedly strong 
positivity within the epithelioid tumor tongues of sunitinib-sensitive xenografts, compared with the 
spindledmorphology of thesametumor (Fig.6F, G). Overall,ourdataindicatedthatspheroidformationvia 
cadherin-mediatedcell–cellcontactenhancedtheviability and proliferation of RCC spheres under 
sunitinib treatment.Thisobservationisinagreementwiththeemergence of E-cadherin–positive tumor 
areas on sunitinib-treated xenografts. 
DISCUSSION 
Theantiangiogenicsunitinibremainsthestandardofcare for mRCC. We followed initial molecular and 
morphologic changes under sunitinib treatment to identify alterationsthat couldberelevant 
todevelopingresistance. Sunitinibresistancehasbeenstudiedextensivelyusing 
xenograftmodels.However,inmostexperimentaldesigns the sunitinib-sensitive phase was represented 
by tumors thathavebeenterminatedveryearly,toavoidbuildingup resistance.Inthatsetup,drug-
sensitivetumorsweregiven farlesstimetogrowinthehost.Moreover,thetimewhen each sunitinib-
sensitive xenograft would enter the resistant phase cannot be foreseen, creating an essentially diverse 
pool of the drug-sensitive tumor cohort. We, therefore, believe that the comparison between 
sunitinibresistanttumorsandxenograftsthatgrowataslowerpace under treatment (sunitinib sensitive in 
our experimental setup) is a more relevant representation of sunitinib sensitivity because it allows the 
study of the dynamics of treatment response. Additional limitations of the xenograft model are the 
use of immunodeficient mice and the preferentialselectionforaggressivetumorswhencelllines 
areestablished. Sunitinib response was characterized based on the tumor growth curve, and treatment 
resistance was defined as a rapid growth phase after an initial response. Using 3 RCC model cell lines, 
we did not find truly sunitinib-sensitive xenografts that completely halted 
theirgrowthundertreatment.Alltumorsbecamelarger over the duration of the experiment, mimicking 
the clinical scenario, in which the median of progressionfreesurvivalinpatientsis8–
9mo,anddurableresponse is rare. The most prominent histologic change between theinvivosunitinib-
andvehicle-treatedxenograftswas thepresenceofepithelioidtumortonguesvs.thediffuse necrotic 
spaces observed in the control tumors. The extentofsurvivingepithelioidislandscorrespondedto the 
sensitive or resistant states. Morphologic and IHCbasedsimilaritiesbetweenthein vitrospheroidsandin 
vivo tumor islands that survive sunitinib treatment provided initial evidence that these patterns were 
related. Additionally, among the different model cell lines, a close correlation was apparent among the 
spheroid-forming ability, the xenograft’s histologic appearance, and the duration of in vivo drug 
response. DMSO-treated Renca cells formed many spheroids in vitro, which were reflected by the high 
frequency of spheroid-like islands in the vehicle-treated xenografts. Accordingly, Renca tumors quickly 
developed spectacular epithelioid tumor tongues upon sunitinib treatment, which was pairedwitha 
veryshortsunitinibsensitive phase. ACHN and 786-O cell lines had a 
moderateorlowcapacityforspontaneousspheroidformation 
invitro,whichparalleledtherareepithelioidorspheroidlikemorphologyintheuntreatedxenograftsandwit
han extended sunitinib-sensitive period. Our results are in agreement with previous reports that 
suggested a nongenetic base for sunitinibresistance(25). Time-lapse microscopy, mRNA analysis, and 
a metastatic colonization assay show that sunitinib hasapreferential effect on the adherent RCC 
pattern, compared withthespheroids.Allourresultspointedinthesame direction: the spheroid 
architecture is beneficial for cancercellsurvivalundertreatment.Thepresenceofa spheroid-associated 
signature in adherent sunitinibtreated cells suggests that sunitinib primes RCC cells for 
spheroidformation.Ourdataimplythatcellsthatsurvive sunitinib treatment switch the RTK-based 
activation of PI3K/AKT to alternative inputs, such as GPCRs and cell-adhesion complexes, to ensure 
continued activity and survival. Indeed, GPCRs, such as the calcitonin receptor-like receptor and GPCR 
162, are significantly up-regulated in RCC, their expression correlates with poor prognosis (26–28), and 
they affectthe carbohydrate metabolism–AKT-mTOR axis, the quintessential RCC 
driver(29).Morespecifically,our resultsindicatetheupregulation of the GPCR CDC42, a primary 
regulator of cell polarity and cytoskeletal organization in renal 
epithelialtubularcellsduringembryogenesis(30).Similarly, sunitinib-treated gastrointestinal tumors 
showed elevatedphospho-AKT(31). RCC spheroids showed epithelioid characteristics and highly 
expressed Ca2+-dependent cell–cell adhesion proteins,suchasE-
cadherin.Thisresultseeminglycontradicts reportsthatstressthenecessityofEMTandmesenchymal 
features to gain aggressive tumor features and drug resistance(6,32–
35).Recently,however,severallaboratories reported a more-complex relation between EMT and cancer 
(36). Several studies suggest that EMT is not a prerequisite for metastasis. Genetic tracing of cells that 
underwent EMT and, in an independent study, the deletion of Snail and Twist revealed that EMT is not 
compulsoryfortheinitiationofprimaryandmetastatic luminal breast adenocarcinoma and pancreatic 
ductal adenocarcinoma (36, 37). 
RCC cells likely reside in anintermediate gray zone of the EMT spectrum and are known to coexpress 
mesenchymal (vimentin) and epithelial (low-MW CK, panCK, and EMA) markers. Recent data show that 
in some cancers, including RCC, expression of the mesenchymal signature and lack of epithelial 
signature correlated with better disease-free and overall survival (38). 
Additionally,RCCcaseswithamore-mesenchymalgenesignature responded better to compounds 
targeting microtubule dynamics, indicating that the epithelioid compartment has a differential 
response for various drugs (38). Lastly,itispossiblethatabalanceexistsbetweenthelessproliferative, but 
more therapy-resistant epithelioid pattern,and the more-proliferativemesenchymalpattern. Despite 
membranous E-cadherin expression, RCC spheroid cells did not appear to be differentiated, polarized 
epithelia. RCC spheroid cells were tightly packed, which may indicate loss of polarity and deficiency of 
microtubular structure and cytoskeletal network. Alternatively, these epithelioid islands and the 
budding phenotype on the tumor front may reflect a discrete form of invasion. For example, during 
renal embryonicdevelopment,epithelioidcellclusterscollectively 
migrateduringnephricductelongation,highlightingthe migratorypotential of epithelioidcells(39–41). 
Ourresultsshowthatsunitinib-resistanceisinducedin thetreatment-
sensitivestage,andnonrespondingcellscan be morphologically identified at this early time point. These 
findings mayhavefuture implications where sunitinib is used as part of a combination therapy. Several 
ongoing trials assess sunitinib or other antiangiogenic 
RTKsincombinationwithnivolumaborpembrolizumab (42). Reportedly, sunitinib itself has immune 
modulatory effect by suppressing regulatory T (Treg) cells and could, therefore, be used in sequential 
therapeutic strategies to prime antitumor immune response (43). Antitumor 
immuneresponsecanalsobegeneratedbyoncolyticviruses, and that response is augmented by sunitinib 
(44). However, our data and that of others show that, in sunitinib resistance, the tumor acquires 
molecular signatures that promote tumor survival and may affect the tumor’s immunologic properties 
and thus the effectiveness of the subsequent immunotherapy. During sunitinib resistance, the tumor 
acquires molecular signatures that promote tumor survival under treatment and may affect the 
tumor’s immunologic properties and thus the effectiveness 
ofthesubsequentimmunotherapy.Understanding which histologic and molecular characteristics 
dominate during early and late phases of sunitinib response may be exploited in the future to optimize 
interference between TKIandimmunetherapy(42). 
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Figure Legends 
Figure 1. Common histologic changes are present in sunitinib-sensitive and resistant 
xenografts compared with vehicle-treated tumors. A) Tumor growth curves of vehicle-treated, 
sunitinib (SU)-sensitive, and SU-resistant Renca and 786-0 xenografts. Lines depict the ﬁtted 
slope of tumor growth curves. B) Compact cancer tongues interrupted necrotic spaces in SU-
sensitive and resistant xenografts. Arrows indicate live tumor islands. Surviving tumor areas 
within the necrotic spaces expressed epithelioid markers, such as PanCK and low-MW CK 
(LMWCK). Tumors also stained positively for the mesenchymal marker vimentin (VIM) and the 
renal marker PAX8. 
 
Figure 2. Sunitinib increases tumor spheroid formation in vitro. Renca and ACHN cells were 
treated with sunitinib (SU) or with vehicle. A, B) Treated cells showed signiﬁcant increase in 
tumor spheroid formation. Number of spheroids, adherent cells, and spheroid-forming cells 
were quantiﬁed by ImageXpress, on Hoescht-3422–stained cultures. A representative picture 
of vehicleand SU-treated cultures. Cell nuclei were stained by Hoechst 3342 to enable 
automated spheroid and cell counting by ImageXpress (B). Spheroids are highlighted as light-
blue areas. C) Number of tertiary spheres formed under vehicle- or SU treatment. D) 
Percentage of cells that participate in spheroid formation under vehicle- or SU treatment. 
 
Figure 3. Sunitinib has a distinct effect on adherent and spheroid growth patterns of RCC in 
vitro. The effect of sunitinib on adherent and spheroid growth patterns of ACHN cellswas 
followed by time-lapse microscopy. A) Four conditions were evaluated. Condition 1 was 
vehicle-treated cells; condition 2, sunitinib treatment; condition 3, vehicle-treated cells were 
switched to sunitinib treatment; and condition 4, sunitinib-treated cells were switched to 
vehicle-treatment. Time-lapse microscopy start point was at 0 h, and cultures were followed 
for 55 h. B) Representative photographs of the time-lapse microscopy. Yellow dotted line 
outlines the border of the adherent RCC areas. Spheroids are shown with orange arrows, 
whereas adherent growth is denoted by white arrows. C) Quantitative representation of 
changes in the percentage of area covered by adherent and spheroid patterns under the 4 
conditions. 
 
Figure 4. Overlapping cellular processes are predicted to operate under sunitinib treatment 
and spheroid formation. Transcriptome analysis indicates that cell–cell adhesion, cytoskeletal 
organization, vesicular transport, and cellular polarity are similarly altered during spheroid 
formation (A) and sunitinib treatment (B). Additionally, sunitinib treatment is predicted to 
induce the PI3K/AKT survival pathway through GPCRs. 
 
Figure 5. In vitro RCC spheroids and in vivo tumor islands surviving sunitinib (SU) treatment 
are related. A) 786-0 spheroids (786) or adherent cells were assessed for E-cadherin (E-CAD) 
and b-catenin expression by immunocytochemistry. Nuclei were visualized with DAPI staining. 
B) Vehicle-treated, SU-sensitive, and SU-resistant xenografts were assessed for E-CAD and b-
catenin expression by IHC. Arrowheads indicate membranous positive staining. C–M) Adherent 
(adh) RCC cells or spheroids were xenografted. Tumor morphology was compared on 
hematoxylin and eosin–stained sections. Adh ACHN xenografts appear to be high-grade 
tumors with diffuse necrotic cores and necrotic cores with mainly spindled morphology (C–E). 
Spheroid (sph)-initiated tumors show large, compact tumor tongues, similar to the SUtreated 
xenografts (F–H). The border of sph-based xenografts shows epithelial nests invading adjacent 
tissue (H). Black arrows indicate epithelial tumor nests (G, H). Sph-derived xenografts exhibit 
different histologic patterns, such as cytoplasmic clearing and areas with giant multinucleated 
cells (I, J). Black arrows indicate giant cells. Sphderived and SU-treated Renca xenografts show 
multifocal tumors with compact sph-like patterns (K–M). In contrast, adherent Renca cell 
xenografts have uninterrupted necrotic space. 
